Caladrius Licenses Cell Therapy Tech to AiVita
News May 27, 2016
In return, Caladrius will receive certain development milestone payments as well as royalties on sales of any commercial product. This transaction supports the Company’s strategy to monetize non-core assets. Under the license agreement AiVita will assume responsibility for all costs to develop a product using the licensed intellectual property, including the maintenance costs of the associated intellectual property.
The license contributes to AiVita’s intellectual property protection for its next generation immunotherapy targeting cancer stem cells. AiVita intends to begin a Phase II clinical trial to evaluate the efficacy of its novel approach for ovarian cancer in 2016. To facilitate these clinical objectives, AiVita has also assumed a sublease of the Company’s former Irvine, California facility. This sublease obligation will cover for the remainder of the lease term all cash obligations of Caladrius with respect to the rent and overhead of the Irvine facility.
“Licensing this technology to AiVita is another step forward in streamlining our strategic focus and reducing our operating expenses while monetizing non-core assets through royalty and other milestone-driven transactions,” said David J. Mazzo, Ph.D., Chief Executive Officer of Caladrius. “This agreement adds to the one signed in February 2016 whereby we licensed to AiVita exclusive global rights to our cell-derived dermatological technology for topical skin applications.”
New Process to Differentiate Stem Cells into Nucleus Pulposus-Like CellsNews
Researchers at Washington University have developed a new way to transform human induced pluripotent stem cells into nucleus pulposus cells, which are the chief component of intervertebral discs.READ MORE
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
"Superplatelets" Could Help Make Trauma More SurvivableNews
A University of British Columbia bioengineer has developed a potential strategy for endowing platelets with extra powers so they can rise to the occasion and continue coagulation.READ MORE
Comments | 0 ADD COMMENT
16th Annual Conference on Laboratory Medicine and Pathology
Sep 17 - Sep 18, 2018